Starpharma to present at Bell Potter Healthcare Conference

For personal use only

Starpharma to present at Bell Potter Healthcare Conference

Melbourne, Australia; 9 November 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter's network of international and domestic investors, analysts and advisers. The event is available to live- stream via Bell Potter Client Accesson 9 - 11 November.

Starpharma will be presenting an abridged presentation focussing on an overview of the business and recent milestones, including:

• AZD0466, AstraZeneca's first DEP® oncology product - for which AstraZeneca will present two scientific posterseach accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting in December.
• Recent supply arrangements for VIRALEZE™ antiviral nasal spray inVietnamand Italy, and data published in several leading international journals, Virusesand NatureBiotechnology.
• Update on Starpharma's other partnered programs, including itsDEP®Antibody Drug Conjugates (ADC)programs with Merck & Co Inc., DEP® anti-infective program with Chase Sun, and progress with further commercial discussions with leading companies for additional partnered programs, including in the area of DEP® radiopharmaceuticals.
• Brief update on Starpharma's internal DEP® products, including its phase 2 clinical programs for DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan.

The presentation is attached and also available on Starpharma's website.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products

• the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

Media: Sumit Media

Grant Titmus

Mob: [phone] [e-mail]

Starpharma.com|Twitter|LinkedIn

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary [phone] [e-mail]

4-6 Southampton Crescent Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

For personal use only

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

2

ersonal use only

ASX:SPL OTC:SPHRY

Bell Potter Healthcare Conference 2021

9 November 2021

DR JACKIE FAIRLEY

CEO

ersonal use only

Important notice and disclaimer

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. FLEURSTAT BVGEL (VivaGel® BV) for the treatment of BV and relief of symptoms: Ask your pharmacist - they must decide if this product is right for you. Always read the label. Follow the directions for use. Do not use for more than 7 days unless a doctor has told you to. See your doctor if symptoms persist after 7 days or recur within 2 weeks, and if you consider you may be at risk of an STI. See a doctor if you are diabetic or pregnant/breastfeeding (or plan to be). VIRALEZE™ is not approved for sale or supply in Australia. VIRALEZE™: Always read the label and follow the instructions for use. This medical device is a regulated health product which bears, under this regulation, the CE marking. Do not use if you have a history of sensitivity to any ingredients in the formulation. Not for use in children under the age of 12 years. See a doctor If you are pregnant or breastfeeding. Always follow recommendations from health authorities, including vaccination and good hygiene practices, such as the use of masks, physical distancing, and regular handwashing to ensure the best possible protection against respiratory viruses.

2

SPL

SPHRY

A$1.14

407M

~A$460M

~537k

$53.4M

Institutions ~55% Retail ~40% Staff & other ~5%

onlyKey Investment Data

ASX code

OTCQX code useShare price

Shares on issue

Starpharma's dendrimer platform delivers significant optionality with multiple potential revenue streams, valuable products & clinical-stage assets

Through innovative research and development, Starpharma is creating therapies, which have the potential to improve patient health worldwide.

• Unique polymer (dendrimer) platform creating valuable patented healthcare products (>200 patents)
• Deep portfolio of high-value products on-market and clinical stage assets, with near term potential commercial and clinical milestones
• Products address clear unmet medical need for large markets
• Established supply chain and manufacturing
• Proven record of development & commercialization including successful partnerships with leading global companies

Market capitalisation

ersonalDai y average volume (shares)

Cash on hand - as at 30/09/21

Share register

VIRALEZE™ Antiviral Nasal Spray

• Registered for sale in the UK/Europe and India, and available in certain markets online

VivaGel® BV - Registered in >45 countries; Licensed in >160 countries, on-market in the UK, Europe, Asia, South Africa, Australia & NZ

DEP® - a valuable proprietary nanoparticle drug delivery platform creating significant optionality, accelerates path to market and manages investment risk

VivaGel® condom - Approved in Japan, Europe, Australia & Canada

Share price & market cap at 4/11/2021

3